Cellectis (NASDAQ:CLLS) and Oyster Point Pharma (NASDAQ:OYST) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.
Institutional and Insider Ownership
34.1% of Cellectis shares are owned by institutional investors. Comparatively, 65.9% of Oyster Point Pharma shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 36.9% of Oyster Point Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Cellectis and Oyster Point Pharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Oyster Point Pharma||N/A||-130.97%||-43.06%|
Earnings and Valuation
This table compares Cellectis and Oyster Point Pharma’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cellectis||$22.99 million||31.25||-$102.09 million||($2.41)||-7.02|
|Oyster Point Pharma||N/A||N/A||-$45.71 million||($9.97)||-2.68|
Oyster Point Pharma has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Oyster Point Pharma, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and target prices for Cellectis and Oyster Point Pharma, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Oyster Point Pharma||0||0||3||0||3.00|
Cellectis currently has a consensus price target of $32.50, indicating a potential upside of 92.08%. Oyster Point Pharma has a consensus price target of $46.25, indicating a potential upside of 73.22%. Given Cellectis’ higher probable upside, analysts clearly believe Cellectis is more favorable than Oyster Point Pharma.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. It is also developing UCARTCLL1 to treat AML; ALLO-819 for treating AML; UCARTCS1 for the treatment of multiple myeloma (MM); and ALLO-715 to treat MM. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; Cornell University; Dana Farber Cancer Institute; and H. Lee Moffitt Cancer Center. Cellectis S.A. was founded in 1999 and is based in Paris, France.
About Oyster Point Pharma
Oyster Point Pharma, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. It is involved in developing OC-01, a nicotinic acetylcholine receptor agonist that is in Phase IIb clinical trial to treat the signs and symptoms of dry eye disease, as well as Phase III clinical trial for the neurotrophic keratitis. The company was founded in 2018 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.